文献速递神经免疫

乌布妥昔单抗治疗多发性硬化五年:ULTIMATE I和II开放标签扩展研究

Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.
PubMed 文献 · JAMA Neurol · 2026-01-01

ULTIMATE I和II随机双盲期显示乌布妥昔单抗较特立氟胺显著降低复发型多发性硬化疾病活动,开放标签扩展至5年发现持续临床获益,年复发率低至0.045,残疾进展比例低,安全性与既往一致。

要点

  • 乌布妥昔单抗治疗5年时年复发率降至0.045,92%患者无24周确认残疾进展。
  • 早期换用乌布妥昔单抗者年复发率1年内降低58.4%,且持续下降。
  • 严重感染发生率与既往安全性特征一致,免疫球蛋白水平平均保持正常下限以上。

核心结论

  • 乌布妥昔单抗治疗复发型多发性硬化5年显示持续临床获益,支持早期启用高效治疗。

研究设计与样本

  • ULTIMATE I和II为2年多中心随机双盲活性对照3期研究,开放标签扩展研究纳入851例完成双盲期的复发型多发性硬化成人。

主要发现

  • 特立氟胺换用乌布妥昔单抗者1年内年复发率降低58.4%(0.182 vs 0.076;率比0.42;95%CI 0.29-0.60;P<.001)。
  • 第5年时UBL-UBL组24周确认残疾进展为8.0%,TER-UBL组为14.3%(P=.01)。
  • 第5年时UBL-UBL组24周确认残疾改善为17.0%,TER-UBL组为12.2%(P=.02)。
  • 严重感染(除外COVID事件)暴露调整发生率每100参与者年UBL-UBL组2.10、TER-UBL组2.58。

关键数值与推荐

  • 第5年UBL-UBL组年复发率为0.020,TER-UBL组年复发率降至0.045。
  • 92%的UBL-UBL参与者保持无24周确认残疾进展。

临床怎么用

  • 对于复发型多发性硬化,早期启用乌布妥昔单抗可能带来长期低疾病活动度和残疾稳定获益。

局限性

  • 开放标签扩展研究存在选择偏倚,仅纳入完成双盲期并同意继续治疗者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the 2-year Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (ULTIMATE) I and II randomized clinical studies, disease activity was significantly reduced with ublituximab vs teriflunomide in participants with relapsing multiple sclerosis (RMS). OBJECTIVE: To evaluate long-term ublituximab clinical efficacy and safety. DESIGN, SETTING, AND PARTICIPANTS: The 2-year, multicenter, randomized, active-controlled, double-blind period (DBP) of the ULTIMATE I and II phase 3 studies occurred September 2017 to November 2020. Enrollment in the ongoing ULTIMATE open-label extension (OLE) study began November 2019; data cutoff for this analysis was January 1, 2024. INTERVENTION: ULTIMATE OLE participants continued ublituximab (UBL-UBL) or switched from teriflunomide to ublituximab (TER-UBL). MAIN OUTCOMES AND MEASURES: Efficacy (annualized relapse rate [ARR], 24-week confirmed disability progression [CDP24], and 24-week confirmed disability improvement [CDI24]) and safety were key outcomes. RESULTS: Of 985 adults with RMS who completed ULTIMATE I and II, 851 enrolled in the ULTIMATE OLE and were included in the analysis. On DBP completion, more than 85% of participants (UBL-UBL, 422 of 494; TER-UBL, 429 of 491) entered the OLE, of whom more than 70% (UBL-UBL, 297 of 422; TER-UBL, 327 of 429) continued taking ublituximab at year 5 (OLE year 3) at data cutoff, making up the analysis population (mean [SD] age, 38.5 [9.7] years; 532 female [62.5%]). TER-UBL participants experienced a 58.4% ARR reduction at 1 year after the switch (0.182 vs 0.076; rate ratio, 0.42; 95% CI, 0.29-0.60; P < .001), and ARR continued to decrease to 0.048 (year 4) and 0.045 (year 5). UBL-UBL participants had further ARR reductions after the DBP (0.053, 0.032, and 0.020 for years 3, 4, and 5, respectively). At year 5, CDP24 was 8.0% in UBL-UBL participants vs 14.3% in TER-UBL participants (P = .01), and CDI24 was 17.0% in UBL-UBL participants vs 12.2% in TER-UBL participants (P = .02). Adverse events were consistent with the established safety profile from pivotal trials, with exposure-adjusted incidence rates per 100 participant-years of serious infections (excluding COVID events) of 2.10 (UBL-UBL) and 2.58 (TER-UBL). On average, immunoglobulin levels remained above the lower limit of normal, and no significant differences in serious infection rates were observed regardless of immunoglobulin level. CONCLUSIONS AND RELEVANCE: Results reveal that sustained clinical benefits were observed with 5 years of ublituximab treatment: ARR in year 5 showed 1 relapse per 50 participant-years of ublituximab treatment and 92% of UBL-UBL participants remained free from CDP24. Results confirm long-term ublituximab benefits and early initiation of high-efficacy treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04130997.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cree BAC, Fox E, Hartung HP, et al. Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study. JAMA Neurol. 2026. PMID: 41697690. doi:10.1001/jamaneurol.2026.0007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。